Three-Year Experience With KRAS, BRAF, and NRAS Mutations in Colon Cancer: A Single-Center Study

November 3, 2025Genel Tıp DergisiOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate mutation profiles of KRAS, BRAF, and NRAS in colon adenocarcinoma and their associations with clinicopathological parameters.
Retrospective analysis of 100 patients with diagnosed colon adenocarcinoma.
Patients underwent molecular testing for KRAS, BRAF, and NRAS mutations.
Clinicopathological data including age, gender, and tumor characteristics were collected.
KRAS mutations found in 52% of cases; NRAS and BRAF mutations in 6% and 5%, respectively.
No significant associations between KRAS mutation and clinicopathological variables.
NRAS mutations associated with larger tumor diameter.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Single-center study reveals molecular testing of KRAS, BRAF, and NRAS mutations in colon cancer indicates distant metastasis associations.

No takes yet. Share an insight, caveat, or question.

Ömeroğlu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share